Jacobs & Co’s Biogen BIIB Stock Holding History

Jacobs & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,440	Closed	-$2.8M	–	122
2019 Q4	$2.8M	Buy	+9,440	New	+$2.62M	0.43%	71
2015 Q2	–	Sell	-480	Closed	-$202K	–	124
2015 Q1	$202K	Buy	+480	New	+$189K	0.05%	123

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jacobs & Co's BIIB Position: Q1 2020 in Review

Jacobs & Co sold out of Biogen (BIIB) in Q1 2020, closing a stake of 9,440 shares — an estimated $2.8M sold.

Jacobs & Co first reported a position in BIIB in Q1 2015 and held it in 2 quarters. The position peaked at $2.8M in Q4 2019. 1,098 funds tracked by Wall St. Rank hold BIIB as of Q1 2020.

Jacobs & Co reported no remaining Biogen position as of Q1 2020 after selling out during the quarter.
Jacobs & Co sold 9,440 Biogen shares in Q1 2020, an estimated $2.8M.
Jacobs & Co first reported a position in Biogen in Q1 2015 and held it in 2 quarters.
Jacobs & Co's Biogen position peaked at $2.8M in Q4 2019.
1,098 funds tracked by Wall St. Rank held Biogen as of Q1 2020.

Based on Jacobs & Co's 13F filing for Q1 2020, filed 13 Apr 2020.